THE SENATE TWENTY-NINTH LEGISLATURE, 2018 STATE OF HAWAII S.B. NO. 2247

JAN 1 9 2018

A BILL FOR AN ACT

RELATING TO OPIOID ANTAGONISTS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. The legislature finds that the nationwide 2 opioid epidemic continues to result in an alarming number of 3 opioid overdose deaths. According to the Centers for Disease 4 Control and Prevention, opioid overdose fatalities have 5 increased from 33,000 in 2015 to 53,000 in 2016. Unintentional 6 drug poisonings, commonly referred to as drug overdoses, are one 7 of the leading causes of injury-related mortality in Hawaii. 8 Furthermore, an average of four hundred non-fatal overdoses 9 occur in Hawaii per year, and opioid related overdoses resulted 10 in about \$9,800,000 in hospital costs in 2016.

11 The legislature further finds that deaths caused by opioids 12 are often preventable via timely administration of an opioid 13 antagonist, such as naloxone. Studies have found that providing 14 opioid overdose training and naloxone kits can help people 15 identify signs of an opioid-related drug overdose and can help 16 reduce opioid overdose mortality. Thus, there is a need for 17 increased public access to health care professionals who can



safely provide naloxone and related education about the risks of
 opioid misuse.

3 The legislature also finds that pharmacists are well 4 situated to provide education and access to naloxone and assist 5 with the prevention and health care burden of addressing opioid 6 overdose in Hawaii. A good example of how pharmacists can 7 positively impact the overall public health continuum and reduce 8 health care costs is seen with pharmacists providing 9 immunizations. Pharmacists now immunize more patients than any 10 other health care professionals, and immunization rates have 11 grown, reducing disease and morbidity in the overall population. 12 The legislature notes that there is significant precedent 13 in Hawaii law that supports expanded access to opioid 14 antagonists and the role of registered pharmacists in the administration, dispensing, and prescription of opioid 15 antagonists, such as in Act 66, Session Laws of Hawaii 2017, Act 16 17 68, Session Laws of Hawaii 2016, and Act 217, Session Laws of 18 Hawaii 2015.

Accordingly, the purpose of this Act is to expand the scope of registered pharmacists' practices by allowing registered pharmacists to prescribe, dispense, and provide related



Page 3

education of opioid antagonists without the need for a written, 1 2 approved collaborative agreement. 3 SECTION 2. Chapter 461, Hawaii Revised Statutes, is 4 amended by adding a new section to be appropriately designated 5 and to read as follows: 6 "§461- Opioid antagonist; authority to prescribe and 7 dispense; requirements. (a) A pharmacist may prescribe and 8 dispense an opioid antagonist to a patient or family member or 9 caregiver of a patient who is at risk for an opioid overdose 10 regardless of whether the patient has evidence of a previous prescription for an opioid antagonist from a practitioner 11 12 authorized to prescribe opioids. The opioid antagonist 13 prescribed and dispensed for a family member or caregiver of an 14 individual who is at risk for an opioid overdose shall be 15 prescribed and dispensed in the name of "Opioid Antagonist 16 Recipient" or "OAR". 17 (b) A pharmacist who prescribes and dispenses opioid 18 antagonists pursuant to subsection (a) shall: 19 Complete a training program related to prescribing (1) opioid antagonists that is approved by the 20 21 Accreditation Council for Pharmacy Education (ACPE), a



Page 4

1		curriculum-based program from an ACPE-accredited
2		college of pharmacy, a state or local health
3		department program, or a program recognized by the
4		board;
5	(2)	Provide the person who is receiving the opioid
6		antagonist with information and written educational
7		material on risk factors of opioid overdose, signs of
8		an overdose, overdose response steps, and the use of
9		the opioid antagonist;
10	(3)	Obtain an acknowledgment form signed by the person
11		receiving the opioid antagonist. The pharmacist shall
12		notify the practitioner who authorized the original
13		opioid prescription that an opioid antagonist was
14		prescribed and dispensed by the pharmacy. For opioid
15		antagonists that are prescribed to "Opioid Antagonist
16		Recipient" patients, the practitioner shall be
17		notified if applicable. The pharmacy shall maintain
18		the signed acknowledgment form with the prescription
19		record; and
20	(4)	Dispense the opioid antagonist to the individual who
21		is at risk for an opioid overdose, family member, or



S.B. NO. 2247

1	caregiver as soon as practicable after the pharmacist
2	issues the prescription.
3	(c) A pharmacist who prescribes an opioid antagonist
4	pursuant to subsection (a) shall not require the individual who
5	is at risk for an opioid overdose, family member, or caregiver
6	to schedule an appointment with the pharmacist for the
7	prescribing or dispensing of the opioid antagonist."
8	SECTION 3. Section 461-1, Hawaii Revised Statutes, is
9	amended as follows:
10	1. By adding two new definitions to be appropriately
11	inserted and to read:
12	""Caregiver" means an individual who has an established
13	personal or professional relationship with the individual at
14	risk for opioid overdose.
15	"Family member" means an individual who can provide
16	assistance and is related to the individual at risk for opioid
17	overdose."
18	2. By amending the definition of "practice of pharmacy" to
19	read:
•	

20 ""Practice of pharmacy" means:



S.B. NO. 2247

The interpretation and evaluation of prescription 1 (1)orders; the compounding, dispensing, and labeling of 2 drugs and devices (except labeling by a manufacturer, 3 packer, or distributor of nonprescription drugs and 4 commercially legend drugs and devices); the 5 6 participation in drug selection and drug utilization reviews; the proper and safe storage of drugs and 7 8 devices and the maintenance of proper records therefor; the responsibility for advising when 9 10 necessary or where regulated, of therapeutic values, content, hazards, and use of drugs and devices; 11 Performing the following procedures or functions as 12 (2)part of the care provided by and in concurrence with a 13 14 "health care facility" and "health care service" as defined in section 323D-2, or a "pharmacy" or a 15 licensed physician or a licensed advanced practice 16 registered nurse with prescriptive authority, or a 17 "managed care plan" as defined in section 432E-1, in 18 accordance with policies, procedures, or protocols 19 developed collaboratively by health professionals, 20 including physicians and surgeons, pharmacists, and 21



1	regi	registered nurses, and for which a pharmacist has			
2	rece	received appropriate training required by these			
3	poli	cies, procedures, or protocols:			
4	(A)	Ordering or performing routine drug therapy			
5		related patient assessment procedures;			
6	(B)	Ordering drug therapy related laboratory tests;			
7	(C)	Initiating emergency contraception oral drug			
8		therapy in accordance with a written			
9		collaborative agreement approved by the board,			
10		between a licensed physician or advanced practice			
11		registered nurse with prescriptive authority and			
12		a pharmacist who has received appropriate			
13		training that includes programs approved by the			
14		American Council of Pharmaceutical Education			
15		(ACPE), curriculum-based programs from an ACPE-			
16		accredited college of pharmacy, state or local			
17		health department programs, or programs			
18		recognized by the board of pharmacy;			
19	(D)	Administering drugs orally, topically, by			
20		intranasal delivery, or by injection, pursuant to			
21		the order of the patient's licensed physician or			



1			adva	nced practice registered nurse with
2			pres	criptive authority, by a pharmacist having
3	· .		appr	opriate training that includes programs
4			appr	oved by the ACPE, curriculum-based programs
5			from	an ACPE-accredited college of pharmacy,
6			stat	e or local health department programs, or
7			prog	rams recognized by the board of pharmacy;
8		(E)	Admi	nistering:
9			(i)	Immunizations orally, by injection, or by
10				intranasal delivery, to persons eighteen
11				years of age or older by a pharmacist having
12				appropriate training that includes programs
13				approved by the ACPE, curriculum-based
14				programs from an ACPE-accredited college of
15				pharmacy, state or local health department
16				programs, or programs recognized by the
17				board of pharmacy;
18			(ii)	Vaccines to persons between fourteen and
19				seventeen years of age pursuant to section
20				461-11.4; and



1	(iii) Human papillomavirus, Tdap (tetanus,	
2	diphtheria, pertussis), meningococcal, and	
3	influenza vaccines to persons between eleve	en
4	and seventeen years of age pursuant to	
5	section 461-11.4;	
6	(F) As authorized by the written instructions of a	
7	licensed physician or advanced practice	
8	registered nurse with prescriptive authority,	
9	initiating or adjusting the drug regimen of a	
10	patient pursuant to an order or authorization	
11	made by the patient's licensed physician or	
12	advanced practice registered nurse with	
13	prescriptive authority and related to the	
14	condition for which the patient has been seen by	У
15	the licensed physician or advanced practice	
16	registered nurse with prescriptive authority;	
17	provided that the pharmacist shall issue written	n
18	notification to the patient's licensed physician	n
19	or advanced practice registered nurse with	
20	prescriptive authority or enter the appropriate	
21	information in an electronic patient record	



1		system shared by the licensed physician or
2		advanced practice registered nurse with
3		prescriptive authority, within twenty-four hours;
4	(G)	Transmitting a valid prescription to another
5		pharmacist for the purpose of filling or
6		dispensing;
7	(H)	Providing consultation, information, or education
8		to patients and health care professionals based
9		on the pharmacist's training and for which no
10		other licensure is required; or
11	(I)	[Dispensing an opioid antagonist in accordance
12		with a written collaborative agreement approved
13		by the board, between a licensed physician and a
14		pharmacist who has received appropriate training
15		that includes programs approved by the ACPE,
16		curriculum based programs from an ACPE-accredited
17		college of pharmacy, state or local health
18		department programs, or programs recognized by
19		the board;] Prescribing and dispensing an opioid
20		antagonist pursuant to section 461- ;



S.B. NO. 2247

1	(3)	The offering or performing of those acts, services,
2		operations, or transactions necessary in the conduct,
3		operation, management, and control of pharmacy; and
4	(4)	Prescribing and dispensing contraceptive supplies
5		pursuant to section 461-11.6."
6	SECT	ION 4. Section 328-16, Hawaii Revised Statutes, is
7	amended a	s follows:
8	1.	By amending subsections (a) to (c) to read:
9	"(a)	A prescription drug shall be dispensed only if its
10	label bea	rs the following:
11	(1)	The name, business address, and telephone number of
12		the seller. The business address shall be the
13		physical location of the pharmacy or the dispensing
14		practitioner's office;
15	(2)	Except as otherwise authorized for expedited partner
16		therapy in section $453-52[_7]$ or an opioid antagonist
17		in section 461- , the name of the person for whom the
18		drug was prescribed or the name of the owner of the
19		animal for which the drug was prescribed;
20	(3)	The serial number of the prescription;
21	(4)	The date the prescription was prepared;



S.B. NO. 2247

1	(5)	The name of the practitioner if the seller is not the
2		practitioner;
3	(6)	The name, strength, and quantity of the drug;
4	(7)	The "use by" date for the drug, which shall be:
5		(A) The expiration date on the manufacturer's
6		container; or
7		(B) One year from the date the drug is dispensed,
8		whichever is earlier;
9	(8)	The number of refills available, if any;
10	(9)	In the case of the dispensing of an equivalent generic
11		drug product, the statement "same as (brand name of
12		the drug product prescribed or the referenced listed
13		drug name)", or words of similar meaning;
14	(10)	In the case of the dispensing of an interchangeable
15		biological product, the statement "interchangeable
16		with (brand name of the biological product prescribed
17		or the referenced biological drug name)", or words of
18		similar meaning; and
19	(11)	Specific directions for the drug's use; provided that
20		if the specific directions for use are too lengthy for
21		inclusion on the label, the notation "take according



Page 13

to written instructions" may be used if separate
written instructions for use are actually issued with
the drug by the practitioner or the pharmacist, but in
no event shall the notation "take as directed",
referring to oral instructions, be considered
acceptable.

7 If any prescription for a drug does not indicate the number of 8 times it may be refilled, if any, the pharmacist shall not 9 refill that prescription unless subsequently authorized to do so 10 by the practitioner. The act of dispensing a prescription drug 11 other than a professional sample or medical oxygen contrary to 12 this subsection shall be deemed to be an act that results in a 13 drug being misbranded while held for sale.

14 In addition to the requirements enumerated in (b) 15 subsection (a), a prescription drug shall be dispensed only: 16 (1) By a pharmacist pursuant to a valid prescription $[\tau]$ or section 461-1, 461- , or [section] 453-52; 17 18 (2) By a medical oxygen distributor pursuant to a 19 prescription or certificate of medical necessity; 20 provided that the drug to be dispensed is medical 21 oxygen; or



S.B. NO. 2247

1	(3)	By a prac	titioner to an ultimate user; provided that:
2		(A) Exce	pt as otherwise authorized for expedited
3		part	ner therapy in section 453-52, the
4		prac	titioner shall inform the patient, prior to
5		disp	ensing any drug other than a professional
6		samp	le, that the patient may have a written,
7		oral	ly ordered, or electronically transmitted or
8		conv	eyed prescription directed to a pharmacy or a
9		medi	cal oxygen distributor of the patient's own
10		choi	ce;
11		(B) The	practitioner shall promptly record in the
12		prac	titioner's records:
13		(i)	The prescription in full;
14		(ii)	The name, strength, and quantity of the
15			drug, and specific directions for the drug's
16			use;
17		(iii)	The date the drug was dispensed;
18		(iv)	Except as otherwise authorized for expedited
19			partner therapy in section 453-52[7] or for
20			an opioid antagonist in section 461- , the
21			name and address of the person for whom the



1		drug was prescribed or the name of the owner
2		of the animal for which the drug was
3		prescribed; and
4		(v) Prescription drugs dispensed or prescribed
5		for expedited partner therapy as authorized
6		under section 453-52[+] or for an opioid
7		antagonist in section 461- ;
8	(C)	The records described in subparagraph (B) shall
9		be subject to the inspection of the department or
10		its agents at all times; and
11	(D)	No undisclosed rebate, refund, commission,
12		preference, discount, or other consideration,
13		whether in the form of money or otherwise, has
14		been offered to the practitioner as compensation
15		or inducement to dispense or prescribe any
16		specific drug in preference to other drugs that
17		might be used for the identical therapeutic
18		indication.
19	(c) A pr	escription may be communicated in writing, orally,
20	or by electron	ic transmission, and shall include the following
21	information:	

S.B. NO. 2247

1	(1)	The autho	he authorization of the practitioner noted as		
2		follows:	ollows:		
3		(A) Writ	ten prescriptions shall include the original		
4		sigr	nature of the practitioner;		
5		(B) Oral	prescriptions shall be promptly recorded by		
6		the	pharmacist or medical oxygen distributor and		
7		shal	l include the practitioner's oral code		
8		desi	gnation; and		
9		(C) Elec	tronic prescriptions shall be irrefutably		
10		trac	eable to the prescribing practitioner by a		
11		reco	gnizable and unique practitioner identifier		
12		such	as:		
13		(i)	A bitmap or graphic image of the		
14			prescriber's handwritten signature and the		
15			prescriber's oral code designation (or		
16			license number or other identifier if the		
17			prescriber is an out-of-state practitioner);		
18		(ii)	An electronic signature;		
19		(iii)	A digital signature; or		
20		(iv)	By other means as approved by the director;		
21	(2)	The date	of issuance;		



Page 17

1	(3)	The practitioner's name, business telephone number,
2		and business address, unless the practitioner is
3		otherwise uniquely identified and the pharmacy or
4		medical oxygen distributor dispensing the prescription
5		has the prescriber's contact information on file
6		accessible within the dispensing area;
7	(4)	The name, strength, and quantity of the drug to be
8		dispensed, and specific directions for the drug's use;
9	(5)	Except as otherwise authorized for expedited partner
10		therapy in section 453-52[$_{7}$] or for an opioid
11		antagonist in section 461- , the name and address of
12		the person for whom the prescription was written or
13		the name of the owner of the animal for which the drug
14		was prescribed, unless the pharmacy or medical oxygen
15		distributor dispensing the prescription has the
16		address on file accessible within the dispensing area;
17	(6)	The room number and route of administration, if the
18		patient is in an institutional facility; and
19	(7)	The number of allowable refills, if the prescription
20		is refillable. If the number of refills authorized by
21		the practitioner is indicated using the terms "as



S.B. NO. 2247

1	nee	ded" or "prn", the prescription may be refilled up
2	to	twelve months from the date the original
3	pre	scription was written. After the twelve-month
4	per	iod, the "as needed" or "prn" prescription may be
5	ref	illed for a subsequent three-month period;
6	pro	vided:
7	(A)	The prescription is refilled only once during the
8		three-month period;
9	(B)	The refill does not exceed a thirty-day supply of
10		the drug;
11	(C)	The refill does not provide any amount of the
12		drug fifteen months beyond the date the original
13		prescription was written;
14	(D)	In the case of medical oxygen, the duration of
15		therapy indicated on a certificate of medical
16		necessity shall supersede any limitations or
17		restrictions on refilling; and
18	(E)	Subparagraphs (A) to (D) shall apply only to
19		pharmacies and medical oxygen distributors
20		practicing in the State."
21	2. By a	mending subsection (g) to read:



S.B. NO. 2247

1	" (g)	Any drug other than medical oxygen dispensed pursuant
2	to a pres	cription shall be exempt from the requirements of
3	section 3	28-15 (except paragraphs (1), (9), (11), and (12), and
4	the packa	ging requirements of paragraphs (7) and (8)), if the
5	drug bear	s a label containing:
6	(1)	The name and address of the pharmacy;
7	(2)	The serial number and the date of the prescription or
8		of its filling;
9	(3)	The name of the practitioner;
10	(4)	Except as otherwise authorized for expedited partner
11		therapy in section 453-52[$_{7}$] or for an opioid
12		antagonist in section 461- , the name of the patient;
13	(5)	The directions for use; and
14	(6)	Any cautionary statements contained in the
15		prescription.
16	This exem	ption shall not apply to any drug dispensed in the
17	course of	the conduct of a business of dispensing drugs pursuant
18	to diagno	sis by mail, or to a drug dispensed in violation of
19	subsectio	n (a), (b), (c), or (d)."
20	SECT	ION 5. Section 328-17.6, Hawaii Revised Statutes, is
21	amended a	s follows:



1	1.	By amending subsections (c) and (d) to read:
2	"(C)	Any pharmacist or medical oxygen distributor who
3	fills or	refills a prescription from an out-of-state
4	practitio	ner shall:
5	(1)	Note the following on the prescription record: the
6		out-of-state practitioner's full name, address, and
7	•	telephone number;
8	(2)	Be responsible for validating and verifying the
9		practitioner's prescriptive authority by virtue of a
10		valid out-of-state license, a Drug Enforcement
11		Administration registration number, or other measures
12		as appropriate; and
13	(3)	Except as otherwise authorized for expedited partner
14		therapy in section 453-52[$_{7}$] or for an opioid
15		antagonist in section 461- , demand proper
16		identification from the person whose name appears on
17		the prescription prior to filling the prescription, in
18		addition to complying with any identification
19		procedures established by the department for filling
20		and refilling an out-of-state prescription.



1	(d)	Befo	re refilling a transferred out-of-state
2	prescript	ion,	a pharmacist or medical oxygen distributor shall:
3	(1)	Exce	pt as otherwise authorized for expedited partner
4		ther	apy in section 453-52[,] <u>or for an opioid</u>
5	•	anta	gonist in section 461- , advise the person whose
6		name	appears on the prescription that the prescription
7		on f	ile at the originating out-of-state pharmacy or
8		medi	cal oxygen distributor may be canceled; and
9	(2)	Reco	rd all information required to be on a
10		pres	cription, including:
11		(A)	The date of issuance of the original
12			prescription;
13		(B)	The number of refills authorized on the original
14			prescription;
15		(C)	The date the original prescription was dispensed;
16		(D)	The number of valid refills remaining and the
17			date of the last refill;
18		(E)	The out-of-state pharmacy's or out-of-state
19			medical oxygen distributor's name, telephone
20			number, and address, and the original



1	prescription number or control number from which
2	the prescription information was transferred; and
3	(F) The name of the transferor pharmacist or the
4	medical oxygen distributor's agent."
5	2. By amending subsection (f) to read:
6	"(f) An out-of-state prescription record shall state the
7	date of filling or refilling and, except as otherwise authorized
8	for expedited partner therapy in section $453-52[_7]$ or for an
9	opioid antagonist in section 461- , the local address of the
10	person whose name appears on the prescription."
11	SECTION 6. Section 328-17.7, Hawaii Revised Statutes, is
12	amended by amending subsection (a) to read as follows:
13	"(a) Every practitioner, pharmacist, or medical oxygen
14	distributor who compounds, sells, or delivers any prescribed
15	drug to a patient or a patient's agent shall maintain records
16	that identify:
17	(1) The specific drug product dispensed, including:
18	(A) The product's national drug code (NDC) number; or
19	(B) The brand name or the established name and the
20	name or commonly accepted abbreviation of the



1		principal labeler of the drug product dispensed,
2		the product strength, and the dosage form;
3	(2)	The quantity of the drug;
4	(3)	Directions for use;
5	(4)	The number of allowable refills;
6	(5)	The date of initial dispensing and the dates of all
7		refilling;
8	(6)	The date of any transfer of the prescription;
9	(7)	The name, business address, and telephone number of
10		the recipient pharmacist or medical oxygen distributor
11		for any transfer of prescription;
12	(8)	The prescribing practitioner, including name, business
13		address, and telephone number;
14	(9)	The format (oral, written, or electronic) in which the
15		prescription was received;
16	(10)	Except as otherwise authorized for expedited partner
17		therapy in section $453-52[_7]$ or for an opioid
18		antagonist in section 461- , the patient, including
19		name, address, and telephone number;
20	(11)	The date of prescribing; and




S.B. NO. 2247


1	(12) The name of the practitioner, pharmacist, or medical
2	oxygen distributor dispensing the drug.
3	Every prescription dispensed shall have the name of the
4	pharmacist, dispensing practitioner, or medical oxygen
5	distributor responsible for the dispensing appended to the
6	prescription record, and every prescription record shall be
7	preserved and legible for a period of not less than five years.
8	The prescription records shall be subject at all times to the
9	inspection of the director of health or the director's agent."
10	SECTION 7. Statutory material to be repealed is bracketed
11	and stricken. New statutory material is underscored.
12	SECTION 8. This Act shall take effect upon its approval.
13	\bigcirc

INTRODUCED BY:

too be teach -C undo, the N



Will Zuro



Report Title:

Opioid Antagonists; Prescriptions; Dispensing; Pharmacists

Description:

Authorizes pharmacists to prescribe and dispense an opioid antagonist to patients and to family members and caregivers of opioid patients without the need for a written, approved collaborative agreement.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

